Raytheon awarded $71 million in Navy contracts for missile systems
CHICAGO - GE HealthCare (NASDAQ:GEHC), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $35.32 billion, announced Thursday the commercial availability of its new floor-mounted digital X-ray system, Definium Pace Select ET, designed to address staffing challenges and workflow inefficiencies in radiology departments. According to InvestingPro analysis, the company maintains strong financial health with a GOOD overall rating, supporting its continued investment in innovation.
The new system aims to reduce the burden on technologists by automating repetitive tasks and minimizing physical strain in environments where X-ray exams account for 60% of all imaging studies. According to the company’s press release, the system leverages artificial intelligence to ensure accurate patient positioning and consistent image quality. With annual revenues of $19.8 billion and a healthy gross profit margin of 42%, GE HealthCare demonstrates the financial strength to support its technological advancement initiatives.
"With its advanced digital capabilities and automation, Definium Pace Select ET allows technologists of all experience levels to deliver consistent high-quality images to serve the full range of anatomies and patient populations," said Sharad Sharma, Global General Manager, X-ray, at GE HealthCare.
The Definium Pace Select ET features an elevating table, in-room exam control, and automated positioning. The company states the system brings the same high image quality typically found in more expensive overhead tube suspension systems to the more affordable floor-mounted market.
Key features include AI-enabled Helix Advanced Image Processing for image consistency and an Intelligent Workflow Suite that helps prevent errors through automated positioning, protocol selection, and quality checks prior to radiation exposure.
Jyoti Gupta, President & CEO of Women’s Health and X-ray at GE HealthCare, said the launch reinforces the company’s commitment to providing accessible care while alleviating stress from technologists’ workdays.
The announcement comes as healthcare organizations face significant staffing challenges, with 80% reporting being short-staffed and radiology technologists experiencing high vacancy rates, according to information provided in the company statement.
The system has received 510(k) clearance but is not yet CE marked, meaning availability may vary by market. Trading at a P/E ratio of 16.12, GE HealthCare currently trades near its Fair Value, according to InvestingPro analysis. Investors seeking deeper insights into GE HealthCare’s financial metrics and growth potential can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers, along with additional ProTips and detailed financial analysis.
In other recent news, GE HealthCare Technologies Inc. announced the issuance of $1.5 billion in senior unsecured notes, comprising $650 million in 4.800% notes due in 2031 and $850 million in 5.500% notes due in 2035. The company also declared a quarterly cash dividend of $0.035 per share, payable on August 15, 2025, to shareholders of record as of July 25, 2025. Additionally, the U.S. Food and Drug Administration approved an updated label for GE HealthCare’s Vizamyl, enhancing its capabilities to quantify amyloid plaque density in the brain. BTIG reiterated its buy rating on GE HealthCare stock, emphasizing the company’s stable growth trajectory in the medical imaging sector. Further developments include the integration of GE HealthCare’s proprietary features with MIM Encore software, aimed at improving digital imaging and workflow solutions in various medical departments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.